GlassScriptPhysician profile
Hetal Mehta
NPI 1114363587
$9,937.84
in general payments reported to CMS, 2019-2025
21 companies · $2,882 in 2025
The $2,882 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $2,567 · 2021: $1,592 · 2022: $954 · 2023: $574 · 2024: $855 · 2025: $2,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539 · Travel and Lodging: $1,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.70 |
| Travel and Lodging | $1,772.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,134.77 | 2021-2025 | Triclip, Navitor, Ultreon |
| Edwards Lifesciences Corporation | $1,905.05 | 2019-2025 | Sapien 3 Ultra Resilia, Pascal |
| Medtronic, INC. | $1,893.57 | 2021-2025 | Corevalve Evolut R, V-Loc 180 |
| Boston Scientific Corporation | $1,185.21 | 2019-2020 | |
| Medtronic Vascular, INC. | $614.86 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $254.13 | 2021-2025 | |
| Shockwave Medical, INC | $147.76 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $147.61 | 2019-2025 | Farxiga, Wainua |
| Abiomed | $141.03 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $95.31 | 2019-2025 | Eliquis |
| Cardiovascular Systems INC. | $81.23 | 2019 | |
| Merck Sharp & Dohme LLC | $77.79 | 2021-2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $53.31 | 2024 | Opsumit, Uptravi |
| Amgen INC. | $38.43 | 2023-2024 | Repatha |
| Cardiva Medical, INC. | $35.38 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.44 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $24.03 | 2024 | Injectafer |
| Terumo Medical Corporation | $24.00 | 2023 | Navicross, Glidewire, Angio-Seal |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.31 | 2022-2024 | Lifevest |
| W. L. Gore & Associates, INC. | $19.64 | 2023 | Gore Viabahn Vbx Balloon Expandable Endo |
| Janssen Pharmaceuticals, INC | $17.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hetal Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.